drugset / Trial / NCT01337050
Asian Phase I Study Of PF-03446962
Non-randomizedSingle-groupOpen-labelBasic science
Summary
This is an Asian Phase 1, multi center, open label, single arm study of PF 03446962 with dose escalation and designed to define the Maximum Tolerated Dose \[MTD\] and the Recommended Phase 2 Dose \[RP2D\].
Timeline
- Start
- 2011-07
- Primary completion
- 2013-12
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASCRINVACUMAB | Monoclonal antibody | — | Intravenous |